These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 11451550)

  • 61. Correctly timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program.
    Grochowski D; Wołczyński S; Kuczyński W; Domitrz J; Szamatowicz J; Szamatowicz M
    Gynecol Endocrinol; 2001 Jun; 15(3):234-8. PubMed ID: 11447736
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Effects of dyslipidemia on IVF/ICSI pregnancy outcome in patients with polycystic ovary syndrome].
    Li X; Ding W; Liu JY; Mao YD; Huang J; Wang W; Ma X
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):402-408. PubMed ID: 29961283
    [No Abstract]   [Full Text] [Related]  

  • 63. Day two post retrieval 1500 IUI hCG bolus, progesterone-free luteal support post GnRH agonist trigger - a proof of concept study.
    Vanetik S; Segal L; Breizman T; Kol S
    Gynecol Endocrinol; 2018 Feb; 34(2):132-135. PubMed ID: 28933569
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.
    Griesinger G; Verweij PJ; Gates D; Devroey P; Gordon K; Stegmann BJ; Tarlatzis BC
    PLoS One; 2016; 11(3):e0149615. PubMed ID: 26950065
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Comparison of gonadotrophin-releasing hormone analogues and human chorionic gonadotrophin for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case-control study.
    Lewit N; Kol S; Manor D; Itskovitz-Eldor J
    Hum Reprod; 1996 Jul; 11(7):1399-402. PubMed ID: 8671474
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effects of different doses of letrozole on the incidence of early-onset ovarian hyperstimulation syndrome after oocyte retrieval.
    He Q; Liang L; Zhang C; Li H; Ge Z; Wang L; Cui S
    Syst Biol Reprod Med; 2014 Dec; 60(6):355-60. PubMed ID: 25192259
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome.
    Chen CD; Chao KH; Yang JH; Chen SU; Ho HN; Yang YS
    Fertil Steril; 2003 Jul; 80(1):86-90. PubMed ID: 12849806
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors.
    Lyons CA; Wheeler CA; Frishman GN; Hackett RJ; Seifer DB; Haning RV
    Hum Reprod; 1994 May; 9(5):792-9. PubMed ID: 7929724
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Blastocyst development and pregnancies after IVF of mature oocytes retrieved from unstimulated patients with PCOS after in-vivo HCG priming.
    Son WY; Yoon SH; Lee SW; Ko Y; Yoon HG; Lim JH
    Hum Reprod; 2002 Jan; 17(1):134-6. PubMed ID: 11756376
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls.
    Enskog A; Nilsson L; Brännström M
    Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):196-201. PubMed ID: 11384807
    [TBL] [Abstract][Full Text] [Related]  

  • 73. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
    Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
    Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The clinical efficacy and efficiency of a 100-IU starting dose of recombinant follicle stimulating hormone (Puregon) in Korean women undergoing in vitro fertilization and embryo transfer.
    Moon SY; Kim SH; Ku SY; Jee BC; Choi YM; Lee JY
    J Obstet Gynaecol Res; 2003 Jun; 29(3):174-9. PubMed ID: 12841702
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
    Radesic B; Tremellen K
    Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization.
    Schmidt DW; Maier DB; Nulsen JC; Benadiva CA
    Fertil Steril; 2004 Oct; 82(4):841-6. PubMed ID: 15482757
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Elevated interleukin-10 and sex steroid levels in peritoneal fluid of patients with ovarian hyperstimulation syndrome.
    Manolopoulos K; Lang U; Gips H; Braems GA
    Eur J Obstet Gynecol Reprod Biol; 2001 Dec; 99(2):226-31. PubMed ID: 11788177
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers.
    Queenan JT; Veeck LL; Toner JP; Oehninger S; Muasher SJ
    Hum Reprod; 1997 Jul; 12(7):1573-6. PubMed ID: 9262299
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Limited ovarian stimulation (LOS), prevents the recurrence of severe forms of ovarian hyperstimulation syndrome in polycystic ovarian disease.
    El-Sheikh MM; Hussein M; Fouad S; El-Sheikh R; Bauer O; Al-Hasani S
    Eur J Obstet Gynecol Reprod Biol; 2001 Feb; 94(2):245-9. PubMed ID: 11165733
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.